Recent Updates
Recently added Catalysts
SRRK Neutral Sentiment

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Key Takeaway: Scholar Rock is set to announce its financial results for the first quarter of 2026 on May 7, 2026. This report will provide insights into the company's performance and financial health. Investors and stakeholders will be keen to analyze the results for future projections.
Price reaction · baseline $49.32 (2026-04-15 close) · hit after-hours · 2 other SRRK headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.7%
average across 5 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
Apitegromab
Phase 3 · Spinal Muscular Atrophy

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open.
The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website athttp://investors.scholarrock.com.
To participate via telephone, please register in advancehere. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.
An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar RockScholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more atScholarRock.comand follow @ScholarRock on X and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar RockInvestors and others should note that we communicate with our investors and the public using our company websitewww.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Last updated: Apr 16, 2026